Pharmaceutical-funded global health programs are being used as cover to influence international policy and market access decisions.

The claim that pharmaceutical-funded global health programs are being used as cover to influence international policy and market access decisions is a complex issue that involves multiple facets of the pharmaceutical industry and global health governance. Pharmaceutical companies indeed play a significant role in global health through funding and partnerships, which can influence policy and market access. According to a report by the Congressional Budget Office, pharmaceutical companies' R&D spending is influenced by anticipated global revenues and policies that affect drug demand and supply CBO Report. Additionally, the U.S. government is a major player in global health, providing significant funding and support for health initiatives worldwide, which can also shape international health policies KFF Global Health. Furthermore, a study published by Deloitte highlights the importance of market access strategies for pharmaceutical companies, emphasizing that successful market access is crucial for product launch success and can affect pricing, contracting, and reimbursement strategies Deloitte Insights. While these activities are part of legitimate business strategies, they can also lead to concerns about undue influence on health policies and market access decisions. It is important to critically assess these influences to ensure that global health policies are made in the best interest of public health rather than being unduly swayed by commercial interests.